Peter Leeds is the
Authority on penny stocks!

Peter Leeds is the author of 'Penny Stocks for Dummies,' and 'Invest in Penny Stocks.'

Get the honesty and integrity
Peter Leeds brings to investing.

Peter Leeds guarantees that they never accept payment from the stocks they profile.

Want even more?
For $19 per month, you get:

world-famous stock picks

buy/sell opinions + updates

Peter's personal trades

Peter Leeds Stock Picks ($19.99)

Save hours with buy/sell price opinions.

Keep informed with ongoing updates.

Profit from our full analysis team.

Peter Leeds Express (FREE)

Where the stock market is going next.

Money-making insights.

Surprising strategies and tactics.

Latest Blog : Penny Stock Pick IsoRay (ISR)

Read It

High Quality Stocks

You will get:

new picks weekly

buy/sell trading prices

ongoing updates

company reports

phone and e-mail support

No commitment

There is no commitment. If you don't like what you see, simply cancel and don't pay another cent!

We do not provide individual advice.

Penny Stock Trading Newsletter, $19.99/mth

Our penny stock trading newsletter specializes in high quality shares under $5.

Profit as we reveal the best undiscovered companies of the highest quality. We do not provide individual advice. These low-priced shares are trading for $5 or less, some as little as a few pennies.

All picks:

Are High Quality Companies

Are Our Best Picks Ready to Increase in price

Each of our penny stock trading picks has passed Leeds Analysis and is much more likely to multiply in value in the short term.

As we say, great quality
always rises to the top!
Even brand new to trading, you get all the tools you need to be successful.

Did you know?

Peter Leeds and his team take no compensation from the companies they review. (Most other newsletters do, especially the free ones. How can you trust them?)

All Peter Leeds high quality penny stock picks come with the 100% Unbiased Guarantee, stating that our research is completely impartial.

And don't forget - when it comes to the best high quality stocks, Peter Leeds and his team are the most well known, most trusted source for investors to learn which shares to buy.

Remember, Peter Leeds and his team have:

Been around for over two decades!

Sold well over 35,000 subscriptions

Been featured across all top media

This is a group who truly know what they are doing!

Peter Leeds strictly maintains that all of his employees abide by the ethics and moral code he leads with. There has never been, nor will there ever be, a single penny in compensation for any of the stocks they profile. In this way, you know you can trust the honesty and integrity which the Peter Leeds team brings to bear.

Your Penny Stock Trading Advantage

When it comes to the best companies to buy, Peter Leeds is the only choice. With a full team, you will be shown opinions on which companies are best, and gain instant access to all the daily updates, full company reports, and buy and sell prices.

In fact, if you want to try any of the numerous, unproven, flash-in-the-pan services, you are truly putting your money at risk. Selecting the best companies is something that Peter Leeds and his team take very seriously, and now you can benefit from all their hard work for an extemely low price!

The best picks to buy are the ones profiled by Peter Leeds!
Get started with high quality stocks to buy right now!

Penny Stock Pick IsoRay (ISR)

by Peter Leeds

Read all the past Blog entries here

This was our pick last month, IsoRay (ISR).  Congratulations to Peter Leeds subscribers!

Below is the original report in full as originally released:

We'll try to keep it relatively short, but we could go on all day about this one.  IsoRay (ISR) is a biotech penny stock, with lots of cash in the bank, low debt, and some revenue-generating technologies which are saving lives.  

IsoRay (ISR)
Recent Price:  $1.56
Buy Opinion:  1.50 - 1.60
Short Term Sell Opinion:  2.10 - 2.40
Long Term Sell Opinion:  2.50 - 3.50

Here's the lowdown, but then we'll get right into the good stuff.
IsoRay Medical has some proprietary technologies to treat cancers.  What's unique is they have found a method of delivering radioactive chemo therapies internally... at the source.  Their brachytherapies are often used in conjunction with conventional treatments, or on their own.
The target market includes anyone suffering from brain, head, neck, prostate, ocular, lung, and gynecological cancers.  So, in other words, eventually every human being.  Sorry to get dark there, but with the aging of the population, and the advancements in ISR's efficacy, the demographics are tilting the field in IsoRay's favor.
Let us level with you for a minute - there are hundreds of interesting biotech stocks.  Over 90% are losing money as they try to develop their technologies.  The vast majority will be unsuccessful.  We've turned our nose up on hundreds.  
But the difference with ISR, besides the great results they are achieving, is that they are financially rock solid.  Even if they bled cash for the next 5 years, they would still be able to afford doing what they are doing.  
Tip:  Cash Bleed
How much money the company uses in their operations, after taking revenues into account.

$20 million in cash/assets, no debt, and a bleed rate which is both minimal and decreasing, means investors will get to be around for several speculative spikes - even if the company eventually went to zero!  (Do not be alarmed, we do not expect shares to fall.  We are just trying to illustrate a point).
Their lead technology, Celsium-131, is cutting edge.  Almost everyone agrees that cancer treatments will advance, just as they have since the Dark Ages, and this internal radioactive approach is one example of that.
In our mind, the biggest risk to ISR would be some company or Doctor coming up with a flawless, inexpensive cure for cancer.  That would eliminate ISR's customer base pretty quickly.  However, let's hope that happens - you would lose some money on your shares, but everyone would get to live longer.  Some things are more important than your penny stock profits.
More likely, ISR will continue to grow and demonstrate 'proof of concept,' at which point they are sitting ducks to be swallowed up by the massive multi-billion dollar players in the industry.  We aren't just talking about Pfizer and Novartis.  Even a private company, such as Germany's Boeringer Ingelheim, one of the world's 20 largest pharmaceutical corporations, might swallow up ISR, and wouldn't even blink.

Tip:  Takeover
When bigger companies acquire or buy a smaller company for strategic reasons.  Typically, the purchaser pays a price premium to the seller to encourage current shareholders to sell.  This results in the buyer's shares dipping slightly, while the shares of the company being acquired will rise (at least 10%, usually more).
If ISR gets acquired, shareholders will get an instant price-premium profit.  If ISR is not gobbled up, they will continue to do exactly what they are doing, which is great.  They have been holding the line on total revenues, decreasing costs, and their balance sheet just looks sick (meaning good) for any company, ESPECIALLY for a biotech.
Some of the wonderful numbers include:
Loss over the most recent quarterly period of only $900,000
Revenues in the same quarter of $1.07 million
Gross Income loss of only $38,000
Current Assets of $14 million
Total Assets of $25 million
Current Liabilities of $1 million
Total Liabilities of $2 million
$90 million market cap is soo small in an industry full of whales
Forward 12 month P/E is a ridiculously low 23 (with P/E low is better)
Revenues in the last 12 months is over $4 million
Tip:  Financial Ratios
A ratio is simply one number divided by another, in order to provide additional information.  For example, the share price divided by the company's earnings is their price/earnings ratio (P/E).  Financial Ratios allow comparison of companies of all sizes - you could compare IBM to some obscure penny stock, and know which one is stronger based on P/E, or any other ratios you choose.  There are dozens of financial ratios which display a stock's liquidity, activity, leverage, performance, or valuation.

Keep in mind, it is less expensive and less problematic for pharma companies to acquire the smaller businesses which are on to something, than it is for them to develop the technology themselves.  (Not to mention the patents, executive talent, and customer base which comes with the takeover).

Taking a look into Technical Analysis, what was interesting was the trading volume spikes with each price spike over the last year.  This means there are a lot of investors with their eyes on this one, who are just ready to pile in with each report of good news or strong results.  You may want to be involved with the shares of ISR early, in order to benefit with each upcoming price spike.
Penny stocks are risky.  Biotechs are even riskier.  But once in a while the stars align, making the upside potential of the investment even stronger.


This communication, and any comments by Peter Leeds, his company, or his team in any way is NOT intended as financial advice. Published statements are opinions only, and merely disinterested information for entertainment purposes.